Malignant neoplasm of urinary bladder
Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation
Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study
Impact of Padcev/Keytruda Momentum on US Sales of Merck KGaA’s Bavencio in Bladder Cancer
Merck KGaA, Bavencio, Padcev, Keytruda, bladder cancer, US sales, pharmaceuticals, oncology
AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study
AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.
CG Oncology’s Immunotherapy Shows Promising Complete Response Rate in Bladder Cancer Patients
CG Oncology, immunotherapy, bladder cancer, complete response rate, clinical trials, cancer treatment.
ImmunityBio’s Anktiva Receives FDA Approval, Set to Rival Merck in Bladder Cancer Treatment
ImmunityBio, Anktiva, FDA approval, bladder cancer, Merck, cancer treatment, Patrick Soon-Shiong.
FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer
FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials
Merck details win for Keytruda in bladder cancer after surgery
Keytruda, Malignant neoplasm of urinary bladder, Surgery specialty